POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
September 20, 2022 21:31 ET
|
POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19
February 06, 2022 22:18 ET
|
POP Biotechnologies, Inc.
BUFFALO, N.Y., Feb. 06, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biopharmaceutical startup, announces the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a...
Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials
July 20, 2021 09:00 ET
|
Zylö Therapeutics
Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the...
Veritas Pharma Provides Corporate Update on Q2 2018
May 31, 2018 03:10 ET
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, May 31, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to provide a corporate update on its...
Earth Science Tech, Inc. Initiates Pre-Launch on its MSN-2 Human Clinical Trials with Clinique Sante Amite
November 14, 2017 12:00 ET
|
Earth Science Tech, Inc.
Doral, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of industrial hemp...